Dr. Swarnendu Biswas*

CLINICAL PREDICTION MODELS FOR IMMUNOTHERAPY BENEFIT IN ADVANCED SOLID TUMORS: CURRENT EVIDENCE, CHALLENGES, AND FUTURE DIRECTIONS IN LOW-RESOURCE SETTINGS

Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced solid tumours by producing durable responses and improving survival across multiple malignancies. However, only a subset of patients derives sustained clinical benefit, while many experi...